Online inquiry

IVTScrip™ mRNA-Anti-CD52, Campath-1H(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ5120MR)

This product GTTS-WQ5120MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets CD52 gene. The antibody can be applied in Chronic lymphocytic leukemia (CLL) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001803.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1043
UniProt ID P31358
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD52, Campath-1H(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ5120MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3073MR IVTScrip™ mRNA-Anti-TFPI, Anti-TFPI(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA Anti-TFPI
GTTS-WQ8768MR IVTScrip™ mRNA-Anti-TNFRSF4, IBI-101(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA IBI-101
GTTS-WQ9014MR IVTScrip™ mRNA-Anti-MST1R, IMC RON-8(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA IMC RON-8
GTTS-WQ9240MR IVTScrip™ mRNA-Anti-MUC1, IMMU-107(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA IMMU-107
GTTS-WQ4728MR IVTScrip™ mRNA-Anti-IL21, BOS161721(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BOS161721
GTTS-WQ494MR IVTScrip™ mRNA-Anti-IGHE, 47H4(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA 47H4
GTTS-WQ1319MR IVTScrip™ mRNA-Anti-MET, ABT-700(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA ABT-700
GTTS-WQ5195MR IVTScrip™ mRNA-Anti-CD22, CAT-8015(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CAT-8015
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW